Blog

Women on semaglutide face the same gastrointestinal side effects as men at similar rates and severity, but face additional sex-specific considerations: contraceptive absorption may be affected, fertility may increase (relevant for women with PCOS), pregnancy and breastfeeding are contraindications, and menstrual cycle changes are reported anecdotally. This article covers the practical implications.

Gastrointestinal Side Effects (Same as Men)

The core side-effect profile is identical between sexes. STEP-1 trial rates in women and men were essentially the same:

Some studies suggest women report nausea slightly more often than men, but discontinuation rates are similar. Management strategies (smaller meals, hydration, slow eating) work the same way for both sexes.

Contraception and Oral Birth Control

Semaglutide slows stomach emptying, which can delay or reduce absorption of orally administered medications — including some oral contraceptives. Wegovy’s FDA prescribing information notes the potential for reduced contraceptive effectiveness with concurrent use.

Practical recommendations from many prescribers:

• Consider non-oral contraception during semaglutide use: IUD (hormonal or copper), implant, injection (Depo-Provera), patch, vaginal ring, or barrier methods
• If continuing oral contraception, discuss timing with your prescriber — taking the pill at the time of day farthest from semaglutide dosing may help
• Use back-up contraception during initial titration and after dose escalations
• Discuss with both your prescriber and gynecologist; coordinate care

The risk is theoretical rather than well-quantified — clinical trial data on contraceptive failure rates during semaglutide use are limited.

Pregnancy: A Hard Stop

Semaglutide is contraindicated in pregnancy. Animal studies show fetal harm at doses comparable to human clinical doses, including reduced fetal weight, skeletal abnormalities, and increased fetal loss.

FDA labeling recommends:

• Discontinue semaglutide at least 2 months before planned conception (due to the long 7-day half-life)
• Use effective contraception during semaglutide treatment
• If you become pregnant unexpectedly while on semaglutide, contact your prescriber immediately for guidance on stopping and monitoring

Pregnancy registries for women exposed to semaglutide are accepting data. If you’ve been exposed, your prescriber can guide enrollment to contribute to safety knowledge.

Breastfeeding

Semaglutide is not recommended during breastfeeding. Animal studies show the drug is present in breast milk, and human data are insufficient to characterize infant risk. Most prescribers recommend either stopping semaglutide or stopping breastfeeding — discuss the trade-offs based on your specific situation.

Fertility Considerations (Women with PCOS)

Women with polycystic ovary syndrome (PCOS) often have insulin resistance and irregular ovulation. Semaglutide improves insulin sensitivity and supports weight loss, both of which can restore ovulation regularity. The unintended consequence:

• Women with PCOS who previously had irregular cycles or were thought to be infertile may begin ovulating regularly
• Pregnancy can occur unexpectedly
• Effective contraception is essential during PCOS treatment with semaglutide if pregnancy is not desired

Conversely, women with PCOS seeking pregnancy may find semaglutide-induced ovulation restoration helpful — but the drug must be stopped before conception due to fetal risk. Discuss with your prescriber and reproductive endocrinologist.

Menstrual Cycle Changes

Anecdotal reports describe menstrual cycle changes on semaglutide:

• Heavier or lighter periods
• Changes in cycle length
• Spotting between periods
• Missed periods (always rule out pregnancy first)

Several mechanisms could contribute:

• Rapid weight loss reduces estrogen production from body fat (adipose tissue is a source of estrogen)
• Changes in body composition affect hormonal balance
• Improved insulin sensitivity may normalize PCOS-related cycle irregularity
• Stress and hormonal disruption from significant weight change

If cycle changes are significant or concerning, see your gynecologist. Always rule out pregnancy with a test if periods stop.

Hair Loss

Hair loss (telogen effluvium — temporary shedding from rapid weight loss) is reported by about 3 percent of weight-loss trial participants on Wegovy versus 1 percent on placebo. Women may notice this more than men due to longer hair length and different styling. The shedding is typically temporary and resolves within 6-12 months after weight stabilizes.

Mitigation strategies:

• Adequate protein intake (0.8-1.2 g/kg body weight)
• Iron-rich foods (or iron supplementation if deficient)
• Zinc, biotin, vitamin D adequacy
• Gentle hair care during shedding period
• Be patient — regrowth follows shedding

“Ozempic Face” Considerations

Rapid weight loss causes facial volume loss — a cosmetic concern often reported more visibly in women. The change is not specific to Ozempic or semaglutide; any rapid weight loss produces it. Slower titration, maintaining adequate protein, and resistance training may help preserve facial volume to some degree.

Bone Density

Rapid weight loss can reduce bone density, particularly in postmenopausal women. Combine semaglutide with weight-bearing and strength exercise to preserve bone health. Discuss bone density monitoring (DEXA scan) with your prescriber if you’re at higher risk.

The Bottom Line

Women on semaglutide experience the same gastrointestinal side effects as men. The most important sex-specific considerations are reproductive: oral contraceptive absorption may be affected (non-oral methods recommended), pregnancy is contraindicated (stop at least 2 months before conception), breastfeeding is not recommended, and PCOS patients may see restored fertility. Menstrual cycle changes and hair loss are common with rapid weight loss but typically temporary. Discuss reproductive planning, contraception, and bone health with your prescriber and gynecologist before starting semaglutide. For more on GLP-1 treatment options, see our hub.

Brand-name semaglutide (Ozempic, Wegovy, Rybelsus) is not going away. What changed is the legal pathway for routine compounded semaglutide, which narrowed when the FDA declared the semaglutide shortage resolved in 2024-2025. Some telehealth platforms stopped offering compounded semaglutide; others pivoted to alternatives. The brand-name drugs remain FDA-approved, widely available, and supported by manufacturer programs.

What’s Actually Happening

The “is semaglutide going away” question typically reflects confusion about three separate things:

1. Brand-name semaglutide: still available, fully approved, actively manufactured by Novo Nordisk
2. Compounded semaglutide via telehealth: availability narrowed after the FDA shortage declaration ended
3. Generic semaglutide: not yet available; patents extend brand exclusivity into the late 2020s

If you’ve seen news headlines about telehealth platforms changing their offerings or the FDA cracking down on compounded GLP-1s, that’s about the second category — not about the brand-name drug going away.

The Shortage Timeline

Semaglutide was added to the FDA Drug Shortage List in 2022 due to overwhelming demand for both diabetes and weight-loss indications. During an FDA-declared shortage, compounding pharmacies are allowed under federal law to produce essentially copies of the brand-name drug to meet patient needs. This is the legal mechanism that supported widespread compounded semaglutide availability through 2022-2024.

Novo Nordisk significantly expanded manufacturing capacity for semaglutide during 2023-2024. By late 2024, the FDA declared the semaglutide shortage resolved. This declaration removed the legal basis for routine compounding under the shortage exception.

What Remains Legal for Compounding

FDA rules still permit compounding semaglutide in specific situations:

• Patient-specific allergies: if a patient has documented allergy to an excipient in brand-name semaglutide, a compounding pharmacy can produce a version without that excipient
• Dose strengths not commercially available: if a patient needs a dose that doesn’t match brand-name pen strengths
• Pediatric or veterinary needs: specific situations where brand-name product is not suitable

These exceptions are narrower than the shortage-period rules and require legitimate medical justification.

FDA Enforcement

The FDA has stepped up enforcement against:

• Telehealth platforms marketing compounded GLP-1s with misleading efficacy or safety claims
• Compounding pharmacies using semaglutide salt forms (sodium, acetate) that are not the same as the active ingredient in approved products
• Products with non-approved additives marketed as enhancements
• Products sold without legitimate prescriber relationships

Patients should verify their compounding pharmacy is state-licensed, the prescription comes from a legitimate prescriber relationship, and the product label clearly identifies all ingredients.

What About Tirzepatide?

Brand-name tirzepatide (Mounjaro, Zepbound) is also not going away — both remain FDA-approved and actively manufactured by Eli Lilly. The compounded tirzepatide situation parallels semaglutide. The FDA declared the tirzepatide shortage resolved in late 2024, narrowing the legal pathway for routine compounded production. Some compounding pharmacies and telehealth platforms continue producing compounded tirzepatide under specific exceptions.

Will There Be Generic Semaglutide?

Generic semaglutide is not expected before the late 2020s. Novo Nordisk holds patents on:

• The semaglutide molecule itself
• The specific peptide modifications that extend its half-life
• The delivery devices (pens) and formulation excipients
• Manufacturing processes

Patent expiration dates vary by jurisdiction and patent type. Generic competition will eventually arrive but is several years away in the US market. Until then, brand-name semaglutide remains the only FDA-approved option.

If You Use Compounded Semaglutide Currently

If you’ve been using compounded semaglutide and are concerned about access:

1. Confirm with your current provider: are they still able to compound semaglutide for you under current FDA rules?
2. Explore brand-name access: insurance coverage, manufacturer savings cards, patient assistance programs
3. Consider alternatives: tirzepatide (compounded or brand), generic liraglutide, or other GLP-1 options
4. Verify pharmacy legitimacy: state licensing, FDA designation (503A vs 503B), product labeling
5. Plan ahead for refills: don’t wait until the last dose to address access changes

The Bottom Line

Brand-name semaglutide (Ozempic, Wegovy, Rybelsus) is not going away — all three remain FDA-approved and widely available through retail pharmacies. The compounded semaglutide pathway narrowed in 2025 when the FDA declared the shortage resolved. Generic semaglutide is years away. If you currently use compounded semaglutide, discuss access continuity with your prescriber and consider transitioning to brand-name or alternative GLP-1 medications. Consult your prescriber for personalized guidance. For more on GLP-1 treatment options, see our hub.

100 units of semaglutide on a U-100 insulin syringe equals 1.0 mL of volume — the full capacity of a standard 1 mL insulin syringe. The mg dose at 100 units depends entirely on the vial concentration: 2.5 mg at 2.5 mg/mL, 5.0 mg at 5 mg/mL, or 10 mg at 10 mg/mL. The 2.5 mg dose closely matches the maximum FDA-approved Wegovy maintenance dose; doses at 5 mg or above are well outside any approved use.

The MG Conversion by Concentration

Why 2.5 MG Is Notable

The maximum FDA-approved Wegovy dose is 2.4 mg weekly. The 2.5 mg dose at 2.5 mg/mL concentration with 100 units volume is a common configuration in compounded semaglutide because it approximates the maximum Wegovy dose using easy round numbers (full syringe, simple concentration).

Some compounding pharmacies and prescribers use this approach to make dose calculation simpler at the maintenance dose phase. Whether 2.5 mg is meaningfully different from 2.4 mg clinically is debatable; the difference is within typical dose-to-effect variability.

Why Higher Concentrations Create Risk

At 5 mg/mL concentration, drawing 100 units delivers 5.0 mg — approximately twice the maximum approved semaglutide dose. At 10 mg/mL, 100 units delivers 10 mg — four times the maximum approved dose.

Symptoms of semaglutide overdose:

• Severe persistent nausea and vomiting
• Dehydration leading to acute kidney injury
• Severe abdominal pain (possible pancreatitis)
• Hypoglycemia (especially if combined with insulin or sulfonylureas)
• Dizziness, confusion, weakness

If you suspect an overdose, contact poison control (1-800-222-1222 in the US) or seek emergency medical attention.

How to Verify Before Drawing 100 Units

Before drawing a 100-unit dose, confirm:

1. Your prescription specifies this dose in mg. Get the prescription in mg, then calculate units based on your vial concentration.
2. Your vial concentration is what you think it is. Read the label every time, especially after refills.
3. The math checks out. Concentration (mg/mL) × volume (mL) = mg dose. 100 units × your concentration ÷ 100 = your mg dose.
4. The mg dose is within FDA-approved range. Maximum approved is 2.4 mg for Wegovy weight-loss; 2 mg for Ozempic diabetes.
5. Your prescriber confirmed this specific dose. Communicate dose changes in BOTH mg and units.

If You Need More Than 100 Units

For compounded semaglutide at lower concentrations (1 mg/mL), reaching the maintenance dose may require more than 100 units, which exceeds the capacity of a standard 1 mL insulin syringe. Options:

• Use a 3 mL syringe (typically marked in tenths of mL rather than units)
• Switch to a higher concentration vial (your pharmacy can typically accommodate)
• Use brand-name pens which deliver the dose pre-measured in a single injection

Splitting the dose across two injections is rarely appropriate — most semaglutide dosing protocols assume single weekly injection. Discuss with your prescriber and pharmacist before changing injection technique.

Filling a 100-Unit Dose

Steps for drawing the full 100 units (using a standard 1 mL U-100 insulin syringe):

1. Wash hands and prepare clean work surface
2. Wipe vial rubber stopper with alcohol pad
3. Pull syringe plunger to 100 units while needle is in air
4. Insert needle through vial rubber stopper
5. Push plunger to inject all air into vial
6. Invert vial and slowly pull plunger back to 100 units (the maximum mark)
7. Tap gently to remove air bubbles, then ensure exactly 100 units
8. Withdraw needle, prepare injection site, inject subcutaneously

The full 100-unit volume is at the maximum capacity of the syringe; some users find it easier to use a 3 mL syringe for this volume because there’s less concern about overshooting.

Comparison to Brand-Name Wegovy Maximum

The maximum-dose Wegovy pen (2.4 mg) delivers its dose in approximately 0.75 mL of solution. The pen automates this; you don’t see or measure the volume. The compounded equivalent at 100 units / 2.5 mg / 2.5 mg/mL is a slightly larger volume and uses a vial-and-syringe rather than a pen.

The Bottom Line

100 units of semaglutide on a U-100 insulin syringe is always 1.0 mL of volume. The mg dose depends entirely on the vial concentration: 2.5 mg at 2.5 mg/mL closely matches the maximum approved Wegovy dose, while 5.0 mg or 10 mg at higher concentrations would be dangerous overdoses. Always verify concentration before drawing this volume. Confirm with your prescriber that the dose is appropriate for your situation. For more on GLP-1 treatment options, see our hub.

Semaglutide is pronounced sem-uh-GLOO-tide, with the emphasis on the third syllable. The drug is sold under three brand names in the United States: Ozempic (oh-ZEM-pik) for type 2 diabetes, Wegovy (WEE-goh-vee) for weight loss, and Rybelsus (ry-BEL-sus) for oral type 2 diabetes treatment. All three brand names are owned by Novo Nordisk and contain the same active ingredient — semaglutide.

Syllable-by-Syllable Breakdown

Saying it slowly: “sem” + “uh” + “GLOO” (loud) + “tide” → sem-uh-GLOO-tide.

Common Mispronunciations

Several incorrect versions are common:

• sem-AG-loo-tide — wrong stress (on second syllable instead of third)
• se-MAH-gloo-tide — wrong pronunciation of second syllable (“MAH” instead of schwa)
• sem-uh-gloo-TIDE — wrong stress (on fourth syllable instead of third)
• SEM-uh-glue-tide — overly stressed first syllable

The official pronunciation puts primary stress on “GLOO” — the third syllable.

Why the “-Glutide” Suffix?

The suffix “-glutide” is a drug-class identifier maintained by the World Health Organization International Nonproprietary Names (INN) Programme. All drugs in the GLP-1 receptor agonist class use this suffix. Examples:

Note: tirzepatide uses “-tide” but the “-zep-” infix identifies it as a dual GIP/GLP-1 agonist rather than a pure GLP-1 receptor agonist.

Brand Name Pronunciations

Ozempic — oh-ZEM-pik (3 syllables, stress on second):

• “oh” like the letter O
• “ZEM” stressed, like “Zen” with M ending
• “pik” like the word “pick”

Wegovy — WEE-goh-vee (3 syllables, stress on first):

• “WEE” stressed, like the word “we”
• “goh” like the word “go”
• “vee” like the letter V

Rybelsus — ry-BEL-sus (3 syllables, stress on second):

• “ry” like “rye” (the bread)
• “BEL” stressed, like the word “bell”
• “sus” like “suss”

Why Pronunciation Matters

Pharmacists, prescribers, and patients communicate about medications verbally, and similar-sounding names can be confused with one another. Clear pronunciation reduces the risk of:

• Verbal prescription errors (e.g., confusing semaglutide with similar-sounding peptides)
• Patient confusion at pharmacy pickup
• Telemedicine mishearings during virtual consultations
• Misunderstandings at urgent care or emergency visits

If you’re discussing semaglutide with a healthcare provider for the first time, you can either pronounce it correctly or simply say the brand name (Ozempic, Wegovy, Rybelsus) — both work.

Where the Name Comes From

The name “semaglutide” was created through the World Health Organization International Nonproprietary Names (INN) system, which assigns standardized generic names to new medications worldwide. The components break down as follows:

• “sema-“ — molecule-specific prefix unique to this drug, derived to distinguish it from other GLP-1 receptor agonists in development
• “-glu-“ — references “glucagon-like” peptide, indicating the drug class
• “-tide” — standard INN suffix for peptide-based medications

The naming convention allows medical professionals worldwide to identify the drug class and approximate mechanism just from the name. Future GLP-1 drugs will follow similar conventions: triple-agonist retatrutide (re-ta-TRU-tide) uses the same “-tide” suffix; tirzepatide (tir-ZEP-uh-tide) uses “-tide” while the “-zep-” infix identifies it as a different incretin agonist subclass.

Tips for Medical Conversations

Beyond pronunciation, a few practical tips for talking about semaglutide with healthcare providers:

• Always carry a current medication list with your prescriptions, including brand and generic names
• Mention any related drugs (Ozempic, Wegovy, Rybelsus) you’ve previously tried
• Note your current dose in mg, not just units (especially important for compounded versions)
• Tell providers about compounded vs brand-name versions — they’re treated similarly clinically but have different regulatory considerations
• Bring questions written down so you don’t rely on memory when discussing the drug

Quick Audio Reference Tips

If you’re unsure how to pronounce it during a conversation:

1. Say the brand name instead (Ozempic, Wegovy, Rybelsus are all easier)
2. Spell it: “s-e-m-a-g-l-u-t-i-d-e”
3. Type the name during virtual visits using the chat function
4. Ask the provider: “How do you pronounce it?” — this is a normal question

Healthcare providers are accustomed to patients mispronouncing complex drug names and won’t judge you for asking.

The Bottom Line

Semaglutide is pronounced sem-uh-GLOO-tide with emphasis on the third syllable. The brand names are Ozempic (oh-ZEM-pik), Wegovy (WEE-goh-vee), and Rybelsus (ry-BEL-sus). All three contain the same active ingredient. The “-glutide” suffix identifies the drug class (GLP-1 receptor agonists). When in doubt, use the brand name or simply spell it out. Consult your prescriber or pharmacist for any questions about your medication. For more on GLP-1 treatment options, see our hub.

Semaglutide starts working within the first week — most people notice reduced appetite and earlier satiety within days. Measurable weight loss typically appears in weeks 1-4. Full effect requires reaching the maintenance dose (2.4 mg for Wegovy) which takes 16-20 weeks of titration. A1C reductions for diabetes start within 1-2 weeks but take 8-12 weeks at the maintenance dose to reach full effect because A1C is a slow-moving marker.

The Pharmacology Timeline

Semaglutide’s onset of action involves several overlapping phases:

Hours 1-72: Drug absorbs from the injection site and reaches peak blood levels in 1-3 days. GLP-1 receptors in the gut, pancreas, and brain start engaging immediately. Some people report reduced appetite or food preference changes within the first 24-48 hours.

Week 1: Appetite suppression noticeable in most people. Meal portions naturally shrink. Some report decreased “food noise” and lower interest in previously craved foods.

Weeks 1-5: Drug accumulates toward steady-state blood levels (about 5 weeks at any given dose). Each successive injection adds to the total exposure until steady-state is reached.

Weeks 4-16: Dose escalation phase. Each dose increase produces renewed appetite suppression and often a renewed wave of side effects. Weight loss accelerates as the dose climbs.

Week 17+: Maintenance dose (2.4 mg for Wegovy). Full effect, with steady-state blood levels reached by about week 22.

Weight Loss Timeline (STEP-1 Trial Data)

The STEP-1 trial enrolled 1,961 adults with obesity (without diabetes) on Wegovy 2.4 mg weekly. Average weight loss by timepoint:

These are averages — individual responses vary widely. Some people lose more rapidly; some lose more slowly; about 14 percent did not reach 5 percent weight loss.

A1C Timeline (For Diabetes Indication)

For type 2 diabetes treated with Ozempic, A1C reduction timeline:

• Weeks 1-4 (0.25 mg starting dose): fasting glucose drops; A1C unchanged
• Weeks 5-8 (0.5 mg): A1C starts dropping
• Weeks 9-12 (1 mg): Continued A1C reduction
• Weeks 12-16: Full A1C effect at the 1 mg dose, typically 1.5-2 percentage points lower than baseline
• Weeks 16+ (optional dose increase to 2 mg): Additional 0.4-0.5 percentage point reduction

The lag is partly because A1C reflects average blood sugar over the prior 2-3 months — the test physically cannot show a 2-week change as fully.

What “Working” Means at Each Phase

Days 1-7: Reduced appetite, smaller meals, earlier satiety. These are signs of GLP-1 engagement, not significant weight loss yet.

Weeks 2-4: 1-3 pounds of weight loss from reduced calorie intake. Glucose readings improving.

Weeks 4-12: 4-6 percent body weight loss at higher doses. A1C beginning to drop measurably.

Weeks 12-28: 10-12 percent body weight loss as dose reaches maintenance. Full A1C effect for diabetes.

Months 6-12: Approaching maximum weight loss potential. The rate of loss slows as your body adapts metabolically.

Year 1+: Maintenance and stabilization. Most people who continue semaglutide indefinitely maintain their loss; those who discontinue typically regain.

Factors That Speed Up or Slow Down Effect

Speeds up:

• Strict dietary discipline (eating only when hungry, avoiding sugary drinks)
• Regular physical activity, especially strength training
• Good sleep (7-9 hours nightly)
• Higher starting BMI (more weight to lose initially)
• Reaching maintenance dose without titration interruptions

Slows down:

• High-calorie liquid intake (sodas, juices, alcohol)
• Snacking despite no hunger
• Sedentary lifestyle
• Poor sleep or chronic stress
• Hypothyroidism or other untreated metabolic conditions
• Frequent titration interruptions for side effects

Setting Realistic Expectations

If you expect rapid dramatic weight loss in the first month, you’ll be disappointed. The first month’s loss is typically 1-3 pounds — modest. Significant loss requires reaching the higher doses, which takes months. Patience is essential.

If you’re using semaglutide for diabetes, A1C improvements will be visible at your 3-month follow-up labs. Don’t expect to see them at week 4.

The Bottom Line

Semaglutide starts reducing appetite within the first week, produces measurable weight loss within 4 weeks, and reaches full effect at the maintenance dose around week 17-22. A1C reductions for diabetes appear in 8-12 weeks. Individual responses vary widely; the 16-week titration is essential to minimize side effects. Be patient through the dose escalation period and reassess your progress at the maintenance dose. Consult your prescriber if you have concerns about your specific response. For more on GLP-1 treatment options, see our hub.

If semaglutide is not working for you, the most common reasons are being still in the titration phase, hidden calories overriding appetite suppression, or being a non-responder. About 14 percent of STEP-1 trial participants did not reach 5 percent body weight loss at any point in 68 weeks on Wegovy — meaning a meaningful minority of patients do not respond to semaglutide even with full adherence. Below is a practical troubleshooting framework before declaring the drug a failure for you.

First Question: Are You at Maintenance Dose?

The standard Wegovy titration is 16 weeks long. The starting doses (0.25, 0.5 mg) produce minimal weight loss because they’re designed to acclimate your body, not to produce maximum effect. If you’re 4 weeks in on 0.25 mg and not losing weight, that’s expected — not a treatment failure.

Significant weight loss typically appears in the 1.0-2.4 mg dose range (weeks 9-17+). Average trial participants lost 6 percent body weight by week 12 and 15 percent by week 68 at the 2.4 mg maintenance dose.

If you’re still titrating, give the drug time to reach the maintenance dose. If your prescriber paused your titration due to side effects, discuss whether resuming or finding an alternative makes sense.

Second Question: Are You Eating More Than You Think?

Semaglutide reduces hunger and appetite. It doesn’t override calories — if you consume calories your body doesn’t need, you won’t lose weight regardless of GLP-1 activity.

Common hidden calorie sources:

• Sugary drinks: 200-400 calories per soda, juice, or sweetened coffee drink — easily missed
• Alcohol: 100-200 calories per drink; reduces inhibition around food
• Cooking oils and fats: tablespoon of oil = ~120 calories; easily underestimated
• Snacking despite no hunger: habit eating rather than physiological hunger
• Large portions of healthy food: nuts, avocado, olive oil are nutritious but calorically dense
• Tasting while cooking, finishing kids’ plates: uncounted but real calories

Track everything you eat and drink for one week (use a food tracking app). The result often surprises people. If you’re consuming more than your body needs, semaglutide cannot overcome it.

Third Question: Are You Losing Muscle Instead of Fat?

Rapid weight loss without adequate protein and resistance training causes substantial muscle loss alongside fat loss. Muscle loss lowers your resting metabolic rate, making continued weight loss harder. The scale moves but your body composition gets worse.

Recommendations during semaglutide treatment:

• Aim for 0.8-1.2 g protein per kg body weight per day (higher end for active individuals)
• Strength training 2-3 times per week (full-body or split routine)
• Maintain or increase daily steps and activity
• Monitor body composition (not just weight) — DEXA scans or body fat measurements help

Fourth Question: What About Sleep, Stress, and Hormones?

Poor sleep increases ghrelin (hunger hormone) and decreases leptin (satiety hormone), working against semaglutide’s appetite-reducing effects. Chronic stress raises cortisol, which promotes belly fat storage and increases hunger.

Underlying conditions that can blunt weight loss:

• Hypothyroidism (slows metabolism)
• PCOS (insulin resistance)
• Cushing’s syndrome (rare but possible)
• Certain medications (steroids, some antidepressants, some antipsychotics)
• Menopause (hormonal changes affect body composition)

If you suspect any of these, get bloodwork (TSH, fasting insulin, cortisol if symptoms warrant) to rule them in or out.

Fifth Question: Are You a Non-Responder?

About 14 percent of STEP-1 trial participants did not reach 5 percent body weight loss at any point in 68 weeks on Wegovy. This isn’t well-explained — possible factors include genetics, baseline metabolic profile, gut microbiome differences, or unmeasured behavioral factors. Some people simply do not respond to semaglutide for reasons not yet characterized.

If you’ve been at the 2.4 mg maintenance dose for 12-16 weeks with full adherence and no meaningful weight loss, you may be a non-responder. The next step is often switching to tirzepatide, which works through an additional receptor pathway (GIP) and produces more average weight loss in head-to-head trials. About 65 percent of patients who responded poorly to semaglutide responded better to tirzepatide in clinical observations.

The Plateau Problem

Many people lose weight rapidly in the first 6 months on semaglutide, then plateau. This is normal and reflects metabolic adaptation — your body’s resting metabolic rate decreases as you lose weight, so the calorie deficit needed to continue losing shrinks.

Strategies for breaking a plateau:

• Reassess your calorie intake (your maintenance calories are now lower than they were at your starting weight)
• Add or intensify strength training (preserves and builds metabolically active muscle)
• Increase protein (supports muscle maintenance)
• Consider whether dose increase is appropriate (within FDA-approved range)
• Discuss switching to tirzepatide with your prescriber
• Accept that some weight loss plateau is normal and not necessarily a failure

When to Talk to Your Prescriber

Contact your prescriber if:

• You’ve been at the maximum maintenance dose for 12-16 weeks without meaningful weight loss
• You’re experiencing significant side effects without weight-loss benefit
• You’ve audited diet, sleep, and exercise and still see no progress
• You suspect an underlying condition is interfering
• Your insurance situation is changing and you need to plan ahead

A productive appointment includes your weight log, food diary (1-2 weeks), current dose history, and any specific concerns or questions.

The Bottom Line

Semaglutide not working often means still being in titration, hidden calorie sources, muscle loss masking fat loss potential, sleep/stress factors, or being a non-responder. Audit your calories, protect muscle with protein and strength training, address sleep and stress, and rule out underlying conditions. About 14 percent of trial participants did not reach 5 percent weight loss; if you’ve adequately tried the drug at maintenance dose, switching to tirzepatide is a reasonable next step. Consult your prescriber to discuss your specific situation. For more on treatment options, see our hub.

20 units of semaglutide on a U-100 insulin syringe equals 0.20 mL of volume — always. Units on an insulin syringe measure volume, not mass. The mg dose at 20 units depends entirely on your vial concentration: 0.5 mg at 2.5 mg/mL, 1.0 mg at 5 mg/mL, or 2.0 mg at 10 mg/mL. This unit-to-volume-to-mg relationship is the source of most compounded semaglutide dosing errors per FDA safety reports.

Understanding U-100 Insulin Syringes

“U-100” refers to a specific type of insulin syringe designed for U-100 insulin (insulin formulated at 100 units per mL). The marking system on these syringes is:

• 1 mL syringe = 100 units total capacity
• 0.5 mL syringe = 50 units total capacity
• 0.3 mL syringe = 30 units total capacity (often with half-unit markings)

Each tick mark on the syringe represents 1 unit of volume, which equals 0.01 mL. So:

• 20 units = 0.20 mL
• 40 units = 0.40 mL
• 50 units = 0.50 mL
• 100 units = 1.00 mL

These volume relationships are fixed by the syringe markings, independent of what liquid you are measuring.

The MG Conversion Depends on Concentration

To find the mg of semaglutide in 20 units, multiply concentration by volume:

Same syringe markings — vastly different mg doses. This is why concentration verification is so critical.

The Dangerous Misconception

The most dangerous misunderstanding is interpreting “20 units” as 20 mg directly. This would be:

• ~8 times the maximum Wegovy weight-loss dose (2.4 mg)
• ~10 times the maximum Ozempic diabetes dose (2.0 mg)

If you drew up 20 mL of semaglutide solution (the volume that would actually hold 20 mg at standard concentrations), it would be more volume than most insulin syringes can hold. The conceptual error usually presents in someone seeing “20” on a label and assuming it’s mg without checking the syringe markings.

Practical Implications for Your Dose

If your prescriber tells you “take 20 units” you need to know what concentration your vial is at to interpret this correctly. A safer instruction includes both: “take 20 units (0.5 mg) at 2.5 mg/mL concentration.”

If your prescriber tells you “take 0.5 mg” and your vial is at 2.5 mg/mL, you draw 20 units. If your vial is at 5 mg/mL, you draw 10 units. Always do the math fresh for each refill.

How to Verify Your Concentration

Read your vial label carefully. The concentration is typically printed clearly, often near the drug name:

• “Semaglutide 2.5 mg/mL”
• “Semaglutide 5 mg/mL”
• “Semaglutide 10 mg/mL with cyanocobalamin”

Some compounded products list total mg per vial AND volume (e.g., “5 mg / 2 mL”). To calculate concentration, divide: 5 mg ÷ 2 mL = 2.5 mg/mL.

If the label is unclear, contact your pharmacy before injecting. Don’t guess.

What If You Need 20 MG, Not 20 Units?

The maximum approved semaglutide dose is 2.4 mg (Wegovy maintenance). A 20 mg dose would be far above any approved or safe dose and should never be injected. If a prescription or instruction says “20 mg semaglutide,” verify with the prescriber before doing anything — this is almost certainly a typo or transcription error.

Common 20-Unit Scenarios

The Bottom Line

20 units of semaglutide on a U-100 insulin syringe is always 0.20 mL — units measure volume, not mass. The mg dose at 20 units depends on the vial concentration: 0.5 mg at 2.5 mg/mL, 1.0 mg at 5 mg/mL, or 2.0 mg at 10 mg/mL. Always verify concentration before calculating mg from units. Never interpret “20 units” as “20 mg” — that would be a massive overdose. Brand-name pens eliminate this math by delivering pre-measured doses. Consult your prescriber and pharmacist for any dose questions. For more on GLP-1 treatment options, see our hub.

1.7 mg of semaglutide equals 68 units (0.68 mL) on a U-100 insulin syringe at the most common compounded concentration of 2.5 mg/mL. The dose equivalence changes with different vial concentrations: 34 units at 5 mg/mL or 17 units at 10 mg/mL. This dose is the Wegovy week 13-16 titration step, sitting between the 1.0 mg and 2.4 mg maintenance dose. Compounded products require manual math; brand-name pens deliver the dose pre-measured.

The Conversion at Each Common Concentration

Where 1.7 MG Fits in the Wegovy Schedule

Wegovy uses a 16-week titration to minimize gastrointestinal side effects. The 1.7 mg dose sits between 1.0 mg and the 2.4 mg maintenance dose:

If 2.4 mg causes intolerable side effects, some prescribers maintain patients at 1.7 mg as a long-term dose. This is off-label maintenance but produces meaningful weight loss with potentially better tolerability for some patients.

How to Draw Up 1.7 MG (at 2.5 mg/mL Concentration)

1. Wash hands and prepare a clean work surface
2. Wipe the vial rubber stopper with an alcohol pad and let dry
3. Attach a 1 mL U-100 insulin syringe needle (or appropriate small-volume insulin syringe)
4. Pull the plunger back to 68 units while the needle is in air
5. Insert the needle into the vial through the rubber stopper
6. Push the plunger down to inject air into the vial
7. Invert the vial and slowly pull the plunger back to 68 units while the needle tip stays below the liquid surface
8. Tap gently to remove air bubbles, then adjust to exactly 68 units
9. Withdraw the needle, prepare your injection site, and inject subcutaneously

Why Concentration Matters for This Dose

At 1.7 mg, dose-conversion errors have meaningful consequences:

• If you have 2.5 mg/mL but draw 34 units (the 5 mg/mL count), you’d inject only 0.85 mg — half the intended dose
• If you have 5 mg/mL but draw 68 units (the 2.5 mg/mL count), you’d inject 3.4 mg — twice the intended dose, exceeding the maximum Wegovy dose

Always verify concentration on each refill, especially if you’ve recently changed pharmacies or your pharmacy has updated formulations.

Brand-Name Equivalents at 1.7 MG

The Wegovy 1.7 mg pen delivers exactly 1.7 mg per injection with no math required. The pen is identifiable by its specific color/label coding (each Wegovy dose has a unique color). Pens contain a single dose; you don’t measure anything.

The 1.7 mg pen is used during the week 13-16 titration phase of Wegovy treatment. Some prescribers maintain patients at this dose long-term if higher doses cause intolerable side effects.

Compounded Semaglutide Considerations at 1.7 MG

If your compounded semaglutide vial is supplied at 2.5 mg/mL with about 5 mL total volume (a common configuration), the vial contains roughly 12.5 mg of semaglutide. At the 1.7 mg dose, that’s about 7 weekly doses per vial. Plan refills accordingly to avoid running out mid-titration.

Higher concentrations (5 or 10 mg/mL) require fewer mL per dose and more total doses per vial but increase dosing-error risk because each unit represents more mg.

The Bottom Line

1.7 mg of semaglutide equals 68 units at the standard 2.5 mg/mL compounded concentration, 34 units at 5 mg/mL, or 17 units at 10 mg/mL. This dose is the Wegovy week 13-16 titration step toward the 2.4 mg maintenance dose. Always verify the concentration of your specific vial before drawing up the dose. Brand-name Wegovy pens deliver this dose pre-measured with no math required. Consult your prescriber and pharmacist for any dose changes. For more on GLP-1 treatment options, see our hub.

Switching from tirzepatide to semaglutide is straightforward in mechanics but typically means restarting semaglutide at the lowest dose (0.25 mg weekly) and titrating up over 16 weeks. The most common reasons to switch are insurance coverage changes, supply issues, side-effect intolerance to tirzepatide, or cost considerations. Most patients can expect some weight regain or slowed weight loss during the transition, followed by stable progress at the new maintenance dose. Below is a practical guide to the process.

Common Reasons to Switch

• Insurance changes: employer or plan changes coverage; one drug is now covered and the other is not
• Supply shortages: historical Mounjaro/Zepbound shortages drove some patients to semaglutide
• Side-effect intolerance: tirzepatide’s GI side effects too severe; hope semaglutide tolerates differently
• Cost considerations: savings card eligibility, different out-of-pocket math under each plan
• Prescriber preference: some prescribers favor semaglutide’s longer track record for certain patients
• Comorbidity considerations: Wegovy’s cardiovascular risk reduction approval may be relevant for some patients

Standard Switching Protocol

The most common protocol:

1. Take the last dose of tirzepatide on its scheduled day
2. Wait one week (your normal dosing interval)
3. On the day of your next scheduled injection, start semaglutide at 0.25 mg (the standard Wegovy starting dose)
4. Continue the standard Wegovy titration: 0.25 mg for 4 weeks, then 0.5, 1.0, 1.7, and finally 2.4 mg maintenance

Some prescribers use a different approach — for example, starting at a higher semaglutide dose if you were tolerating high-dose tirzepatide well. Always follow your specific prescriber’s instructions.

What to Expect During Transition

Weight loss may slow or partially reverse. The lower starting dose of semaglutide has less appetite-suppression effect than the higher tirzepatide dose you were on. Many patients see 2-5 lbs of regain over the first 4-8 weeks of the switch before weight loss resumes at higher doses.

Side effects may return. Each semaglutide dose escalation may cause renewed nausea, similar to when you first started tirzepatide. The first 1-2 days after each injection tends to be the worst.

Appetite may return. Reduced GLP-1 activity at the lower starting dose means hunger and food cravings may return more strongly. Eating discipline becomes more important during the transition phase.

Equivalent Dose Comparison

The drugs are not directly dose-equivalent, but rough approximate efficacy comparisons:

Note: these are approximate. The drugs have different mechanisms (tirzepatide is dual GIP/GLP-1; semaglutide is GLP-1 only) and the “equivalent” dose concept is imprecise. Even at maximum semaglutide dose, tirzepatide produces more average weight loss.

Expected Weight Loss After Switch

Average weight loss differs between the drugs at maximum doses (per SURMOUNT-5):

• Tirzepatide 15 mg over 72 weeks: ~20% body weight loss
• Semaglutide 2.4 mg over 72 weeks: ~14% body weight loss

Switching from maximum tirzepatide to maximum semaglutide may shift your total trajectory from a 20% goal to a 14% goal — a meaningful difference for many patients. Discuss your expectations with your prescriber.

Managing the Transition

1. Plan timing carefully. Schedule the switch during a low-stress period when you can manage side effects.
2. Maintain hydration. Especially during dose escalation; reduces risk of acute kidney injury.
3. Continue eating discipline. The lower starting dose means weaker appetite suppression — discipline matters more.
4. Track weight weekly. Expect some regain in weeks 1-8; reassess at week 16 when at maintenance dose.
5. Report side effects. If GI symptoms are severe or persistent, your prescriber may slow titration.
6. Don’t compare your week-1 semaglutide to week-72 tirzepatide. You’re starting over from the beginning of the titration curve.

What If the Switch Goes Badly?

If semaglutide produces worse side effects, less weight loss, or other issues:

• Discuss with your prescriber after 12-16 weeks at maintenance dose (need adequate trial time)
• Consider switching back to tirzepatide if insurance allows
• Discuss alternative options (Saxenda/liraglutide, oral agents, surgery referral)

Cost Comparison After Switch

If you switch for cost reasons, verify your math. List prices are similar (~$1,000-$1,400/month). Insurance and savings card eligibility differ between drugs. For commercially insured patients, both manufacturers offer copay assistance — but eligibility rules differ. Run the math with your specific plan and your specific eligibility before assuming one is cheaper.

The Bottom Line

Switching from tirzepatide to semaglutide means restarting at the lowest semaglutide dose and titrating up over 16 weeks. Expect some weight regain during transition and somewhat smaller maximum weight loss at the new drug’s maintenance dose. Most patients tolerate the switch well, but plan for 20-24 weeks to fully stabilize. Discuss timing, expectations, and any concerns with your prescriber before switching. For more on GLP-1 treatment options, see our hub.

Tirzepatide produced an average 6.5 percentage points more weight loss than Wegovy in the SURMOUNT-5 head-to-head trial published in 2024-2025. Both are weekly injections approved for chronic weight management, and both share an essentially identical gastrointestinal side-effect profile. The biggest functional difference is mechanism — Wegovy targets one receptor (GLP-1), while tirzepatide targets two (GLP-1 and GIP) — which appears to drive its larger weight-loss effect. Pricing and insurance coverage are roughly similar.

What Each Drug Is

Wegovy is the brand name for semaglutide 2.4 mg, a GLP-1 receptor agonist made by Novo Nordisk. It was FDA-approved in 2021 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Subsequent approvals expanded use to adolescents 12 and older and added a cardiovascular risk-reduction indication.

Tirzepatide is the active ingredient in two brand names from Eli Lilly:

• Mounjaro — FDA-approved 2022 for type 2 diabetes
• Zepbound — FDA-approved 2023 for chronic weight management, with a 2024 expansion for obstructive sleep apnea with obesity

Tirzepatide is a dual GIP/GLP-1 receptor agonist, acting on both the GLP-1 pathway (like semaglutide) and the GIP pathway (additional incretin hormone). The combined mechanism is theorized to produce stronger metabolic effects.

Head-to-Head Trial: SURMOUNT-5

The SURMOUNT-5 trial randomized 751 adults with obesity (without diabetes) to receive either tirzepatide 15 mg weekly or semaglutide 2.4 mg weekly (the Wegovy dose) for 72 weeks. Tirzepatide outperformed Wegovy on every primary and secondary outcome.

The trial used maximum tolerated doses of each drug. Average percent weight loss was both clinically and statistically significantly larger with tirzepatide.

Dosing Comparison

The mg numbers are not directly comparable because the drugs are different molecules. What matters is the approved dose range:

Tirzepatide’s longer escalation (20 weeks to maximum dose) provides more granular titration steps, which may help tolerability.

Side Effect Comparison

The two drugs share the same gastrointestinal side-effect profile because both signal through GLP-1 receptors. The most common side effects in trials:

Direct comparison in SURMOUNT-5 showed similar rates of side effects and similar discontinuation rates. Individual tolerability varies; some people handle one drug better than the other.

Serious Risks Are Similar

Both drugs carry the same FDA boxed warning about thyroid C-cell tumors based on rodent studies. Both should be avoided in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both carry risks of pancreatitis, gallbladder disease (from rapid weight loss), and acute kidney injury (typically secondary to dehydration from GI side effects).

Cost and Insurance

List prices are similar:

• Wegovy: ~$1,349 per month
• Zepbound: ~$1,059 per month (lower than Wegovy as of 2024-2025)

Insurance coverage varies. Some commercial plans prefer one drug over the other based on negotiated rebates. Medicare Part D does not cover either for weight loss (federal law excludes weight-loss medications), but does cover Wegovy and Zepbound for non-weight-loss indications (Wegovy for cardiovascular risk reduction, Zepbound for obstructive sleep apnea with obesity).

Manufacturer savings programs:

• Wegovy: Novo Nordisk savings card for commercially insured patients (as low as $0 in some cases)
• Zepbound: Eli Lilly Self-Pay program offers vials (lower-cost format) at $349-$499 per month for patients without coverage

Which Should You Choose?

Tirzepatide is more potent on average for weight loss with a longer titration period that may help tolerability. Wegovy has more years of post-market data and additional approved indications (cardiovascular risk reduction). For many patients, the practical choice comes down to insurance coverage and prescriber preference. The clinical data favor tirzepatide for maximum weight loss; Wegovy remains a strong option, especially for patients who tolerate it well or have cardiovascular indications.

The Bottom Line

Tirzepatide produced more weight loss than Wegovy in the SURMOUNT-5 head-to-head trial (20.2% vs 13.7% over 72 weeks). Both drugs are weekly injections with similar side-effect profiles, similar serious risks, and similar pricing. Wegovy has a longer post-market track record and more approved indications; tirzepatide has stronger weight-loss efficacy. The right choice depends on your weight-loss goal, insurance coverage, and tolerability. Consult your prescriber to discuss which fits your situation. For more on weight-loss treatment options, see our hub.